<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24770511</article-id>
      <article-id pub-id-type="pmc">4008065</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20142944</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Alopecia universalis during treatment with leflunomide and adalimumab -
Case report<sup><xref ref-type="fn" rid="fn01">*</xref></sup>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lazzarini</surname>
            <given-names>Rosana</given-names>
          </name>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Capareli</surname>
            <given-names>Gabriela Cunha</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buense</surname>
            <given-names>Roberta</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lellis</surname>
            <given-names>Rute Facchini</given-names>
          </name>
        </contrib>
        <aff> Santa Casa de S&#xE3;o Paulo - S&#xE3;o Paulo (SP), Brazil. </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Rosana Lazzarini, Rua Dr Cesario Mota Jr, 112, Santa
Cecilia, 01221-020 - S&#xE3;o Paulo - SP, Brazil. E-mail:
<email>rosana.fototerapia@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Mar-Apr</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>2</issue>
      <fpage>320</fpage>
      <lpage>322</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>8</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <p>Alopecia areata is a non-scarring form of alopecia that can be localized or
widespread. Its etiology is unknown, but immunological factors are implicated in its
pathogenesis. With the more frequent use of anti TNF&#x3B1; biologic drugs, some alopecia
areata cases during their use have been described. We report a case of universal
alopecia in a patient with rheumatoid arthritis while using adalimumab and
leflunomide.</p>
      </abstract>
      <kwd-group>
        <kwd>Alopecia</kwd>
        <kwd>Alopecia areata</kwd>
        <kwd>Biological therapy</kwd>
        <kwd>Rheumatoid arthritis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Alopecia areata (AA) is a non-scarring form of alopecia, which affects approximately
1.7% of the population.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> The loss of
hair may be localized or widespread and even affect the nail in some cases. Its etiology
is unknown, but immunological factors have been implicated in its pathogenesis, due to
the presence of inflammatory infiltrate of T-lymphocytes around hair follicles seen
through histology, as well as the involvement of cytokines, including tumor necrosis
factor alpha (TNF-&#x3B1;).</p>
      <p>With the more frequent usage of anti TNF-&#x3B1; biological drugs for the treatment of some
diseases like rheumatoid arthritis, psoriasis, Chron's disease and ankylosing
spondylitis, some AA cases after their use have been reported, suggesting a causal
relationship between them.</p>
      <p>We report a case of severe AA, known as alopecia universalis (AU), in a rheumatoid
arthritis patient using Adalimumab and Leflunomide.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Female patient, 66 years old, with a history of rheumatoid arthritis and hypothyroidism,
was referred to our clinic by the rheumatologist, with complaint of loss of all body
hair and alterations in her fingernails for the past six months. She denied having
similar symptoms before. She had been using Adalimumab and Leflunomide for one year due
to rheumatoid arthritis (RA), but as a result of alterations in hair and nails, her
rheumatologist modified the therapeutic scheme, replacing adalimumab by etanercept and
suspending leflunomide, with no clinical picture alteration, and then referred her to
our clinic. During the dermatological exam she presented nonscarring alopecia of
universal distribution, with presence of few hairs, thin and pigmented, around 3 cm
long, on the scalp (<xref ref-type="fig" rid="f01">Figure 1</xref>). All hand nails
presented dystrophy with presence of cupuliform depressions (pitting) (<xref ref-type="fig" rid="f02">Figure 2</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Total absence of hairs on scalp, eyebrows and eyelashes</p>
        </caption>
        <graphic xlink:href="abd-89-02-0320-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Cupuliform depressions on fingernails and some linear hemorrhages</p>
        </caption>
        <graphic xlink:href="abd-89-02-0320-g02"/>
      </fig>
      <p>Dermoscopy of the scalp demonstrated presence of dystrophic hair and black dots, with
some yellowish spots (<xref ref-type="fig" rid="f03">Figure 3</xref>). A diagnostic
hypothesis of AU triggered by usage of anti-TNF drug (adalimumab) and/or leflunomide was
made and a biopsy of scalp was performed. The latest revealed presence of follicles with
superficial, miniaturized hairs involved by a peribulbar perifollicular lymphocytic
inflammatory infiltrate (<xref ref-type="fig" rid="f04">Figure 4</xref>).</p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Dermoscopy of scalp: black dots (yellow arrow) characterizing dystrophic hair and
yellow dots (red rectangle), demonstrating activity of the disease</p>
        </caption>
        <graphic xlink:href="abd-89-02-0320-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Histopathology. Vertical section showing superficial, miniaturized hair follicles
involved by a peribulbar and perifollicular lymphocytic inflammatory infiltrate on
the dermis</p>
        </caption>
        <graphic xlink:href="abd-89-02-0320-g04"/>
      </fig>
      <p>Topical treatment with minoxidil 5% was initiated and the possibility of suspending
etanercept was discussed with the rheumatologists. After 18 months without using the
medications the patient progressed to an intense regrowth of scalp hair, but still with
some alopecia areas (<xref ref-type="fig" rid="f05">Figure 5</xref>).</p>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Hair regrowth after 18 months of follow-up and without use of drugs</p>
        </caption>
        <graphic xlink:href="abd-89-02-0320-g05"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The pathogenesis of AA remains uncertain, but it is believed that a complex autoimmune
mechanism involving T lymphocytes and proinflammatory cytokines, like tumor necrosis
factor alpha (TNF-&#x3B1;), would be responsible for hair growth inhibition due to its
inflammatory action on the hair bulb. Among the immunobiologicals, adalimumab and
etanercept have as their action mechanism the selective inhibition of TNF-&#x3B1; and would be
drugs with possible applicability for the treatment of AA. However, reports in the
literature showed effects, not yet clarified, of these drugs on the hair bulb,
promoting, paradoxically, hair loss.</p>
      <p>Some reports in the literature show the onset of AA during or after usage of anti-TNF
drugs and only one report described the disease being triggered in a patient using
leflunomide alone.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> These reports show
similar incidence between the sexes with development average of AA varying between
24-48h up to 208 weeks after starting medication use, making it difficult to establish a
causal nexus.</p>
      <p>Personal history of AA seems to be a facilitating factor for the onset of new lesions as
reported by Bartels<sup><xref rid="r03" ref-type="bibr">3</xref></sup> and
Posten.<sup><xref rid="r04" ref-type="bibr">4</xref></sup> Suspension of
medication intake seems to be fundamental for hair regrowth.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>Leflunomide is a drug used in the treatment of RA, which hinders the interaction of T
cells with antigen-presenting ones. Its most common collateral effects encompass
diarrhea, nausea, maculopapular exanthema, weight loss, increase in hepatic enzymes and
transitory alopecia. The report that associates the use of this drug with AA informs
that its suspension resulted in complete hair regrowth in the affected area.<sup><xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>Other drugs have been related to the onset of AA, among them, association of pegylated
interferon, ribavirin and haloperidol, whose mechanisms are also not clear.<sup><xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>In the presented case initial suspension of one of the drug (leflunomide) did not alter
the process, making one suppose that the triggering factor still persisted. Replacing
one TNF inhibitor by another did not contribute to improve the clinical picture,
although no therapy had been instituted for AA treatment, at the time. However, around
three months after suspending the use of the medication, the start of hair regrowth was
observed, especially on the scalp. Notwithstanding it being a dermatosis of difficult
treatment, some authors, like Tosti et cols showed that the suspension of these drugs,
followed by specific therapy for AA, seems to be fundamental for hair
regrowth.<sup><xref rid="r05" ref-type="bibr">5</xref></sup> On the other hand, a
recent publication by Zschoce e cols. reported a similar case, associated with the use
of adalimumab, which after the introduction of etanercept did not cause the onset of new
areas of alopecia. This fact made the authors suggest that the effect caused by a
anti-TNF drug might not transfer to another of the same group, fact that was not
observed in the case here described.<sup><xref rid="r08" ref-type="bibr">8</xref></sup></p>
      <p>Based on literature data and on the correlation between the onset of the clinical
picture and the medication used we believe there is a clear relationship between both
events. The patient is currently being followed-up at the rheumatology, where the
possibility of no longer treating RA with anti-TNF medication is being evaluated, with
methotrexate as an option. This substitution would favor AA therapy, for it is also an
option for the treatment of this dermatosis.<sup><xref rid="r09" ref-type="bibr">9</xref></sup></p>
      <p>Due to the increasing number of patients under treatment with drugs that have anti-TNF
properties, the knowledge and reporting of proportionally growing adverse effects turns
out to be important. Furthermore, the recurrence or development of AA in patients under
anti-TNF-&#x3B1; drugs makes it necessary to review the real importance of this cytokine and
of T lymphocytes as important factors in the pathogenesis of AA, as well as the
indication of biologicals for its therapy.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of Interests: none</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial Support: none</p>
      </fn>
      <fn fn-type="other">
        <p>How to cite this article: Lazzarini R, Caparelli GC, Buense R, Lellis RF. Alopecia
universalis during treatment with leflunomide and adalimumab - Case report. An Bras
Dermatol. 2014;89(2):320-2.</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p>Work performed at the Dermatology Clinic of Santa Casa de S&#xE3;o Paulo - S&#xE3;o Paulo (SP),
Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Safavi</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Suman</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Moshell</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Melton</surname>
              <given-names>LJ</given-names>
              <suffix>3rd</suffix>
            </name>
          </person-group>
          <article-title>Incidence of alopecia areata in Olmsted County, Minnesota, 1975
through 1989</article-title>
          <source>Mayo Clin Proc</source>
          <year>1995</year>
          <volume>70</volume>
          <fpage>628</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="pmid">7791384</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Navarro</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Daud&#xE9;n</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Santiago S&#xE1;nchez-Mateos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a-Diez</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Alopecia areata during treatment of psoriasis with adalimumab and
leflunomide: a case and review of the literature</article-title>
          <source>Skin Pharmacol Physiol</source>
          <year>2012</year>
          <volume>25</volume>
          <fpage>107</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="pmid">22301842</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia Bartels</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Worm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burmester</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Sterry</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Blume-Peytavi</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Development of alopecia areata universalis in a patient receiving
Adalimumab</article-title>
          <source>Arch Dermatol</source>
          <year>2006</year>
          <volume>142</volume>
          <fpage>1654</fpage>
          <lpage>1655</lpage>
          <pub-id pub-id-type="pmid">17179003</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Posten</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Swan</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Recurrence of alopecia areata in a patient receiving etanercept
injections</article-title>
          <source>Arch Dermatol</source>
          <year>2005</year>
          <volume>141</volume>
          <fpage>759</fpage>
          <lpage>760</lpage>
          <pub-id pub-id-type="pmid">15967923</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tosti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pazzaglia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Starace</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bellavista</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vincenzi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tonelli</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Alopeia Areata during treatment with biologic agents</article-title>
          <source>Arch Dermatol</source>
          <year>2006</year>
          <volume>142</volume>
          <fpage>1653</fpage>
          <lpage>1654</lpage>
          <pub-id pub-id-type="pmid">17179002</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zschoche</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bidier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hadaschik</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Alopecia areata during treatment with adalimumabe: therapy with an
alternative TNF-alpha inhibitor is possible</article-title>
          <source>J Dtsch Dermatol Ges</source>
          <year>2013</year>
          <volume>11</volume>
          <fpage>450</fpage>
          <lpage>453</lpage>
          <pub-id pub-id-type="pmid">23279686</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottenberg</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Venancie</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Mariette</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Alopecia areata in a patient with rheumatoid arthritis treated with
leflunomide</article-title>
          <source>J Rheumatol</source>
          <year>2002</year>
          <volume>29</volume>
          <fpage>1806</fpage>
          <lpage>1807</lpage>
          <pub-id pub-id-type="pmid">12180755</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kubota</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishikura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jibiki</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Alopecia areata associated with haloperidol</article-title>
          <source>Jpn J Psychiatry Neurol</source>
          <year>1994</year>
          <volume>48</volume>
          <fpage>579</fpage>
          <lpage>581</lpage>
          <pub-id pub-id-type="pmid">7891421</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chartaux</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Joly</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Long-term follow-up of the efficacy of methotrexate alone or in
combination with low doses of oral corticosteroids in the treatment of alopecia
areata totalis or universalis</article-title>
          <source>Ann Dermatol Venereol</source>
          <year>2010</year>
          <volume>137</volume>
          <fpage>507</fpage>
          <lpage>513</lpage>
          <pub-id pub-id-type="pmid">20804893</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
